Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review

Abstract Objectives Brugada syndrome (BrS) is a hereditary channelopathy that affects cardiac electrical signal transmission, with SCN5A gene mutation being the most common cause. Current BrS therapy primarily relies on Implantable Cardioverter Defibrillators, which are limited to arrhythmia prevent...

Full description

Saved in:
Bibliographic Details
Main Authors: Andin Zahrani Pateda, Andi Alika Azzahra, Kuni Zakiyyah Sumargo, Muchtar Nora Ismail Siregar
Format: Article
Language:English
Published: SpringerOpen 2025-05-01
Series:The Egyptian Heart Journal
Subjects:
Online Access:https://doi.org/10.1186/s43044-025-00640-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849312113241096192
author Andin Zahrani Pateda
Andi Alika Azzahra
Kuni Zakiyyah Sumargo
Muchtar Nora Ismail Siregar
author_facet Andin Zahrani Pateda
Andi Alika Azzahra
Kuni Zakiyyah Sumargo
Muchtar Nora Ismail Siregar
author_sort Andin Zahrani Pateda
collection DOAJ
description Abstract Objectives Brugada syndrome (BrS) is a hereditary channelopathy that affects cardiac electrical signal transmission, with SCN5A gene mutation being the most common cause. Current BrS therapy primarily relies on Implantable Cardioverter Defibrillators, which are limited to arrhythmia prevention. Recent research has explored gene therapy as an alternative approach for managing BrS. Resveratrol, a non-ketone polyphenol compound, exhibits cardioprotective effects due to its antioxidant properties, which can influence gene expression through cellular signaling pathways, thereby modulating adeno-associated virus (AAV). This study aims to evaluate the effectiveness of resveratrol in enhancing the induction of AAV-based viral vectors as a potential definitive therapy for SCN5A mutations in BrS patients. Methods A comprehensive literature search was conducted across multiple databases, including PubMed, Google Scholar, ScienceDirect, and PLOS ONE. The final stage involved assessing the eligibility of 47 studies, followed by a full-text review, which included seven studies for further analysis. Results The findings indicate that this therapeutic approach highlights resveratrol’s crucial role as an activator of deacetylase proteins, influencing DNA repair processes, cell cycle regulation, and energy metabolism. Resveratrol facilitates the modulation of Voltage-Gated Calcium Channels, enabling calcium ion (Ca2⁺) influx into cardiomyocytes, thereby maintaining normal cardiac rhythm. Resveratrol enhances AAV-mediated gene delivery and expression through p53 pathway activation. Conclusion Experimental studies have demonstrated that AAV-MOG1 gene therapy can restore sodium channel function, improve cardiac electrophysiological abnormalities, and ameliorate the clinical manifestations of BrS. Thus, resveratrol is potentially an inducer of AAV-mediated gene therapy for BrS.
format Article
id doaj-art-62245c0240214cbb9278cf055b1d55b2
institution Kabale University
issn 2090-911X
language English
publishDate 2025-05-01
publisher SpringerOpen
record_format Article
series The Egyptian Heart Journal
spelling doaj-art-62245c0240214cbb9278cf055b1d55b22025-08-20T03:53:12ZengSpringerOpenThe Egyptian Heart Journal2090-911X2025-05-017711910.1186/s43044-025-00640-4Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative reviewAndin Zahrani Pateda0Andi Alika Azzahra1Kuni Zakiyyah Sumargo2Muchtar Nora Ismail Siregar3Medical Study Program, Faculty of Medicine, State University of GorontaloMedical Study Program, Faculty of Medicine, State University of GorontaloMedical Study Program, Faculty of Medicine, State University of GorontaloDepartment of Cardiology and Vascular Medicine, State University of GorontaloAbstract Objectives Brugada syndrome (BrS) is a hereditary channelopathy that affects cardiac electrical signal transmission, with SCN5A gene mutation being the most common cause. Current BrS therapy primarily relies on Implantable Cardioverter Defibrillators, which are limited to arrhythmia prevention. Recent research has explored gene therapy as an alternative approach for managing BrS. Resveratrol, a non-ketone polyphenol compound, exhibits cardioprotective effects due to its antioxidant properties, which can influence gene expression through cellular signaling pathways, thereby modulating adeno-associated virus (AAV). This study aims to evaluate the effectiveness of resveratrol in enhancing the induction of AAV-based viral vectors as a potential definitive therapy for SCN5A mutations in BrS patients. Methods A comprehensive literature search was conducted across multiple databases, including PubMed, Google Scholar, ScienceDirect, and PLOS ONE. The final stage involved assessing the eligibility of 47 studies, followed by a full-text review, which included seven studies for further analysis. Results The findings indicate that this therapeutic approach highlights resveratrol’s crucial role as an activator of deacetylase proteins, influencing DNA repair processes, cell cycle regulation, and energy metabolism. Resveratrol facilitates the modulation of Voltage-Gated Calcium Channels, enabling calcium ion (Ca2⁺) influx into cardiomyocytes, thereby maintaining normal cardiac rhythm. Resveratrol enhances AAV-mediated gene delivery and expression through p53 pathway activation. Conclusion Experimental studies have demonstrated that AAV-MOG1 gene therapy can restore sodium channel function, improve cardiac electrophysiological abnormalities, and ameliorate the clinical manifestations of BrS. Thus, resveratrol is potentially an inducer of AAV-mediated gene therapy for BrS.https://doi.org/10.1186/s43044-025-00640-4Adeno-associated virusBrugada syndromeResveratrolSCN5A
spellingShingle Andin Zahrani Pateda
Andi Alika Azzahra
Kuni Zakiyyah Sumargo
Muchtar Nora Ismail Siregar
Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
The Egyptian Heart Journal
Adeno-associated virus
Brugada syndrome
Resveratrol
SCN5A
title Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
title_full Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
title_fullStr Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
title_full_unstemmed Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
title_short Effectiveness of resveratrol in inducing adeno-associated virus as a potential definitive therapy for SCN5A mutation in Brugada syndrome: a narrative review
title_sort effectiveness of resveratrol in inducing adeno associated virus as a potential definitive therapy for scn5a mutation in brugada syndrome a narrative review
topic Adeno-associated virus
Brugada syndrome
Resveratrol
SCN5A
url https://doi.org/10.1186/s43044-025-00640-4
work_keys_str_mv AT andinzahranipateda effectivenessofresveratrolininducingadenoassociatedvirusasapotentialdefinitivetherapyforscn5amutationinbrugadasyndromeanarrativereview
AT andialikaazzahra effectivenessofresveratrolininducingadenoassociatedvirusasapotentialdefinitivetherapyforscn5amutationinbrugadasyndromeanarrativereview
AT kunizakiyyahsumargo effectivenessofresveratrolininducingadenoassociatedvirusasapotentialdefinitivetherapyforscn5amutationinbrugadasyndromeanarrativereview
AT muchtarnoraismailsiregar effectivenessofresveratrolininducingadenoassociatedvirusasapotentialdefinitivetherapyforscn5amutationinbrugadasyndromeanarrativereview